display
Dortmund (dpa / lnw) - After the vaccination stop in North Rhine-Westphalia, the German Foundation for Patient Protection has criticized the policy contracts with the pharmaceutical industry as too lax.
"It's a tough business," said board member Eugen Brysch on Thursday of the German press agency.
Not only the most populous federal state of North Rhine-Westphalia and Germany, but all of Europe was surprised that the manufacturer Biontech was temporarily reducing the amount.
There were no negotiations on an equal footing with the pharmaceutical industry.
Brysch said that politicians had their backs to the wall because they wanted to give people a result.
This was partly due to the circumstances in the corona pandemic.
But there were also possibilities: "If you award research funds amounting to several hundred million euros, there would have been a chance to get more commitment," he clarified.
For the patients who are urgently waiting for the vaccination, the preliminary vaccination stop in North Rhine-Westphalia is a fatal signal.
“It's absolutely horrible,” he says.
He pointed out that nationwide millions of people in need of care are cared for at home by their relatives.
display
On Wednesday, NRW imposed a vaccination stop due to delivery delays for the hospitals that should receive the Biontech vaccinations to protect their particularly vulnerable employees.
For this reason, no further initial vaccinations can be given in the nursing homes either.
Brysch praised the fact that half of the vaccine deliveries for the second syringe are still being made in NRW.
It would be extremely dangerous to take the entire amount for first vaccinations.
© dpa-infocom, dpa: 210121-99-116036 / 2